<DOC>
	<DOCNO>NCT03096847</DOCNO>
	<brief_summary>A national , multi-center , open-label , phase IIIb trial determine efficacy safety treatment ribociclib ( LEE011 ) plus letrozole woman men HR+ , HER2-negative advance metastatic breast cancer .</brief_summary>
	<brief_title>Study Women Men With Hormone-receptor Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patient adult , ≥ 18 year old time inform consent sign informed consent trial related activity accord local guideline Patients advanced ( locoregionally recurrent metastatic ) breast cancer amenable curative therapy . Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive HER2negative breast cancer local laboratory . Local pathology sufficient assessment . Patient must either : 1 . Measurable disease , i.e. , least one measurable lesion per RECIST 1.1 criterion ) . 2 . Bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease 3 . Nonmeasurable disease Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Exclusion Criteria Patient receive CDK4/6 inhibitor mTOR inhibitor . Patient known hypersensitivity excipients ribociclib letrozole Patients current inflammatory breast cancer . Patient receive &gt; 1 chemotherapy treatment advanced/metastatic breast cancer Patient receive &gt; 2 endocrine therapy treatment advanced/metastatic breast cancer Patient central nervous system ( CNS ) involvement . If patient fulfil follow 3 criterion she/he eligible trial . 1. complete prior therapy ( include radiation and/or surgery ) CNS metastases ≥ 28 day prior start study 2 . CNS tumor clinically stable time screen 3 . Patient receive steroid enzyme induce antiepileptic medication brain metastasis Patient active cardiac disease history cardiac dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ribociclib</keyword>
	<keyword>LEE011</keyword>
	<keyword>RIBECCA</keyword>
	<keyword>breast cancer</keyword>
	<keyword>breast carcinoma</keyword>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>Letrozole</keyword>
	<keyword>CDK4/6</keyword>
</DOC>